15 May 2020
Authored and Edited by K. Victoria Barker, Ph.D.; Sanam Habib; Maeve O'Flynn
In April 2019, a referral (G 3/19) was made to the Enlarged Board of Appeal (EBA) by the President following the decision of T 1063/18, concerning the patentability of inventions relating to plants and animals and the interpretation of Article 53(b) EPC in combination with Rule 28(2) EPC.
Under Article 53(b) EPC, European patents shall not be granted in respect of plant or animal varieties or essentially biological processes for the production of plants or animals. Rule 28(2) EPC provides that under Article 53(b) EPC, European patents shall not be granted in respect of plants or animals exclusively obtained by means of an essentially biological process. Rule 28(2) EPC was introduced by decision of the Administrative Council and came into force on 1 July 2017.
In the 2015 EBA decisions G2/12 (Tomato II) and G2/13 (Broccoli II), it was held that the non‑patentability of essentially biological processes for the production of plants or animals under Article 53(b) EPC did not extend to products that are exclusively obtained by means of an essentially biological process. In other words, prior to the introduction of Rule 28(2) EPC, Article 53(b) EPC did not prohibit patenting of plants and animals obtained by essentially biological processes. Technical Board of Appeal followed G2/12 and G2/13 in T 1063/18, indicating that new Rule 28(2) EPC had no impact on the interpretation of Article 53(b) EPC. This led to a referral to the EBA to decide which took precedence - the Rules or the Articles.
The EBA has now decided that plants and animals exclusively obtained by essentially biological processes are not patentable after all - contrary to G2/12 and G2/13. The full text of the opinion can be found here.
In the meantime, the key message to take away from this decision is that Article 53(b) EPC prohibits product claims and product-by-process claims directed to plants, plant material or animals if the claimed product is exclusively obtained by means of an essentially biological process or if the process features define an essentially biological process.
It is important to note that G3/19 does not have retroactive effect. It will be interesting to see, however, how G3/19 will affect currently pending and stayed plant-related patent applications and post grant proceedings.
Finnegan will continue to follow this matter. In the meantime, for further information, please do not hesitate to contact one of our IP Practitioners.
Copyright © 2020 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
10th Annual Georgia Asian Pacific American Bar Association Gala
May 29, 2024
Atlanta
IAPP Global Privacy Summit 2024
April 3-4, 2024
Washington
Conference
2nd Annual Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities
March 20, 2024
Boston
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.